Summary
- Here’s how to cure erectile dysfunction with gel medications
- What are Phosphodiesterase Inhibitors
- Some possible side effects of inhibitors
- Topical formulations for erectile dysfunction
- MED2005: gel tolerance and contraindications
- From MED2005 to DermaSys
- How to cure erectile dysfunction with DermaSys MED3000
Here’s how to treat erectile dysfunction with gel drugs
The question how to treat erectile dysfunction can now be answered more quickly and efficiently thanks to phosphodiesterase 5 inhibitors , a group of drugs that have proven to be particularly effective.
Erectile deficit is a recurring or persistent inability to maintain or obtain an erection that is useful for allowing sexual intercourse . It is a disease that in Italy affects 13% of the male population , about 3 thousand people, and that progressively increases with advancing age. What are phosphodiesterase inhibitors
Phosphodiesterase type 5 inhibitors(PDE5i) today represent the first-line treatment for erectile dysfunction . They are drugs that have the effect of relaxing the muscles of the penis in order to increase blood flow and do not cause an erection in the absence of sexual stimulation.
There are several types and all of them are equally effective. The best drug for the patient is based on his personal experience and the frequency of sexual activity.
These agents are estimated to be effective in approximately 70% of patientsand failure rates between 11 and 44% have been reported, depending on the population studied. A meta-analysis of 22 studies, carried out in 2016, involving nearly 163,000 patients, found that the average discontinuation rate was 4% per month. Thus, nearly 50% of patients stopped treatment within the first year. Some possible side effects of PDE5i inhibitors
must be taken between 30 minutes and 2 hours before sexual activity , thus preventing the spontaneity of the act, and are associated with a number of adverse effects , including:
- Headache
- Backache
- Redness of the face
- Visual disturbances
- Other limitations of PDE5-i include potential interactions with food or alcohol and contraindications in patients taking nitrates .
Existing treatments indicating how to cure erectile dysfunction have significant limitations and there remains a strong unmet need for effective local therapy that is easy to administer, fast acting to facilitate spontaneity of sexual activity and well tolerated, with a low risk of systemic adverse effects. Topical formulations for erectile dysfunction
There are other valid alternatives to treat erectile dysfunction, such as topical formulations .
It is a drug, topical glyceryl trinitrate (GTN) , a vasoactive agent that plays a key role in the development of erection, which was chosen for the development of aexperimental topical gel, MED2005, which is applied to the glans .
The MED2005 has a good speed of action , takes effect within 5 minutes in 44.2% of cases in which you try to have sexual intercourse and within 10 minutes in 69.5% of cases. It has therefore proven to be the world’s fastest-acting treatment for erectile dysfunction.
There were no treatment-related serious adverse events or reactions and there were no patients who dropped out of the study due to side effects. MED2005: gel tolerance and contraindications
Overall, 40.4% of patients and 38% of partners reported preferences for MED2005, compared with 22.2% (P = 0.0007) and 22.2% (P = 0.003), respectively, for the placebo. Common contraindications reported by patients and partners were: headache (7.9% and 1.3%, respectively) and nasopharyngitis (5.7% and 0.9%, respectively).
A study carried out on MED2005 showed that the drug was well tolerated : out of 1003 intercourse attempts, only 21 people experienced headaches.
Application site reactions such as glans cold, irritation or pain occurred in less than 1% of patients and no cases of priapism occurred. Likewise, the low incidence of headaches in female partners suggests that the risk of drug transfer to the partner is reduced. From MED2005 to DermaSys
In a subsequent study, called FM57, the efficacy and safety of glyceryl trinitrate (GTN) 0.2%, 0.4% and 0.6% under the name MED2005 was evaluated. The survey involved a sample of 1000 patients with mild, moderate and severe erectile dysfunction in Europe compared to DermaSys® (MED3000). The MED2005 , therefore, showed strong efficacy, safety, rapidity of actionand had a statistically significant impact on participants in the control group of the experiment.
However, the sample of patients treated with the DermaSys® formulation demonstrated superior and clinically meaningful results. Although this placebo does not contain the active ingredient GTN , used in MED2005, it uses active ingredients of proven transdermal technology from DermaSys®, effective in the treatment of erectile dysfunction . These results prompted Futura Medicals to definitely focus on DermaSys® over MED2005. How to cure erectile dysfunction with the DermaSys MED3000 MED3000 and aunique and innovative formulation of DermaSys® composed of volatile and non-volatile solvents . But how to cure erectile dysfunction with this drug
Here is how it works and how to apply MED3000 :
- The gel is applied to the glans during foreplay .
- After a few seconds the volatile solvents evaporate.
- The rapid cooling that follows, and the subsequent warming, stimulate the nerve endings of the glans .
- After about 10 minutes, smooth muscle relaxation is achieved , followed by tumescence and an erection .
The efficacy of MED3000 is remarkable and approaches that of the current first-line therapy in the treatment of erectile deficit, but with significantly fewer adverse events. Topical application is then of particular interest to patients who want a quick onset of action . The lack of drug interactions with prescription products allows the product to be used with other drugs such as nitrates and other cardiovascular drugs.
Furthermore, it can also be used in combination with other products to improve the overall effectiveness for patients. Therefore MED3000 will be of great interest to the medical community.
